In order to avail several benefits, such as increased flexibility, lower cost and gain assistance in meeting the rising demands, stakeholders are relying on contract manufacturing organizations (CMOs) for production of HPAPI and cytotoxic drugs
Roots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drug Manufacturing Market (4th Edition), 2022 – 2035.” The report features an extensive study of the current market landscape and future potential of the HPAPI and cytotoxic drug manufacturing market, over the next decade.
The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report includes:
A detailed assessment of the overall landscape of companies offering contract manufacturing services for HPAPI and cytotoxic drugs.
A detailed competitiveness analysis of HPAPI and cytotoxic drug contract manufacturers.
Elaborate profiles of prominent players offering contract manufacturing services for HPAPI and cytotoxic drugs, across North America, Europe and Asia-Pacific.
An insightful analysis of the recent collaborations within the HPAPI and cytotoxic drug manufacturing industry, from 2014-2022.
A detailed analysis of the recent expansions undertaken by several HPAPI and cytotoxic drug contract manufacturers.
An estimate of the overall installed capacity for the HPAPI manufacturing, based on information reported by various industry stakeholders in the public domain.
A regional capability assessment framework, which compares the HPAPI and cytotoxic drug manufacturing capabilities across key geographies.
A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.
A case study on companies offering manufacturing services for antibody drug conjugates (ADCs).
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Product
Highly Potent Active Pharmaceutical Ingredient
Highly Potent Finished Dosage Form
Company Size
Small
Mid-sized
Large
Very Large
Scale of Operation
Preclinical
Clinical
Commercial
Type of Molecule
Small Molecules
Biologics
Type of Highly Potent Finished Dosage Form
Injectables
Oral Solids
Creams
Others
Key Geographical Regions
North America (US, Canada and Mexico)
Europe (UK, Italy, Germany, France, Spain and Rest of Europe)
Asia-Pacific (China, India and Rest of Asia-Pacific)
Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
Justin Mason-Home (Owner and Director, HPAPI Project Service)
Antonella Mancuso and Maria Elena Guadagno (Vice President and Chief Operating Officer and Business Director, BSP Pharmaceuticals)
Scott Patterson (Vice President Pharma/Bio Technical Support, ILC Dover)
Stacy McDonald and Jennifer L. Mitcham (Ex-Group Product Manager and Ex-Director-Business Development); Abul Khair (Business Development Associate, Catalent)
Roberto Margarita (Business Development Director, CordenPharma)
Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)
Kevin Rosenthal (Ex-Business Head, Formulations and Finished Products, Alphora Research (Acquired by Eurofins))
Mark Wright (Ex-Site Head, Grangemouth, Piramal)
Allison Vavala (Ex-Senior Manager, Business Development, Helsinn)
Valentino Mandelli (Marketing and Sales Manager, Pharma, Cerbios-Pharma)
Javier E. Aznarez Araiz (Ex-Business Development, Idifarma)
Key companies covered in the report.
AbbVie
Abzena
Aenova
Cambrex
CARBOGEN AMCIS
Catalent
Hovione
Intas Pharmaceuticals
Lonza
Pfizer CentreOne
Piramal Pharma Solutions
Scinopharm
STA Pharmaceutical (a WuXi AppTec company)
Syngene
Teva API
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
You may also be interested in the following titles:
DNA Encoded Libraries
Quantum Computing in Drug Discovery Services Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Owing to the growing number of clinical trials and complexities associated with patient enrollment, drug developers are increasingly relying on patient recruitment service providers to expediate the drug development timelines
Roots Analysis is pleased to announce the publication of its recent study, titled, “Patient Recruitment and Retention Services Market (3rd Edition), 2022 – 2035.”
The report features an extensive study of companies engaged in offering patient recruitment services and patient retention services. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:
A general overview of the clinical trials, patient recruitment process, patient recruitment associated services as well as the patient retention strategies employed to prevent drop-out of enrolled individuals from clinical trials.
A brief information on the various types of patient outreach methods used by contract service providers in this domain, to identify and enroll patients in clinical trials.
A detailed assessment of the overall landscape of companies offering patient recruitment and patient retention services.
A detailed competitiveness analysis of patient recruitment and retention service providers, segregated into three peer groups based on company size (small, mid-sized, and large and very large).
Elaborate profiles of prominent players offering patient recruitment and retention service, based in North America, Europe and Asia Pacific.
An analysis of the partnerships that have been inked by stakeholders engaged in this domain, from 2013-2022.
A review of the emerging trends in the patient recruitment industry, including the use of social media, mobile technologies, electronic health records (EHR), real-world evidence (RWE) and artificial intelligence.
A detailed discussion on the key growth opportunities in the field of patient recruitment and retention that are likely to impact the evolution of the market over the coming years.
A case study on regulatory landscape of patient recruitment, highlighting the regulatory process, guidelines and framework.
A brief overview of patient recruitment in clinical trials focused on personalized medicines and rare diseases.
A detailed analysis of the annual demand for study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.
A detailed assessment on the impact of the COVID-19 pandemic on the patient recruitment and retention services market.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Patient Recruitment Step
Pre-screening
Screening
Trial Phase
Phase I
Phase II
Phase III
Phase IV
Therapeutic Area
Cardiovascular Disorders
Oncological Disorders
Infectious Diseases
CNS Disorders
Respiratory Disorders
Hematological Disorders
Dermatological Disorders
Ophthalmic Disorders
Others
Key Geographical Regions
North America
Europe
Asia Pacific
Latin America
Middle East and North Africa
Rest of the World
To get a sample copy of the latest market report, visit
https://www.rootsanalysis.com/reports/245/request-sample.html
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
Susan Fitzpatrick-Napier (Founder and Director, TrialWire)
Kate Shaw (Chief Executive Officer and Founder) and Marco Lassandro (Marketing and Communications Manager, Innovative Trials)
Simon Klaasen (Co-founder and Managing Director, Link2Trials)
Stefan Mayer-Eggersmann (Chief Commercial Officer, Clariness)
Ken Shore (Chief Commercial Officer, Continuum Clinical)
Hagit Nof (Chief Operation Officer and Business Development Officer, nRollmed)
Paul Ivsin (Ex-Managing Director, Seeker Health)
Kasturi Lakhe (Inside Sales Specialist, EVERSANA)
Key companies covered in the report
BBK Worldwide
Continuum Clinical
IQVIA
United BioSource (UBC)
WCG ThreeWire
Clariness
Fidelis Research
Ignite Data
Innovative Trials
Orphan Reach
3H Medi Solution
Buzzreach
Current Medical Information Center (CMIC)
nRollmed
Trialfacts
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/patient-recruitment-and-retention-services-market/245.html
You may also be interested in the following titles:
Oral Proteins and Peptides Market
Single-Use Upstream Bioprocessing Technology / Equipment Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
Driven by the various advantages offered by at-home self-testing kits and the growing awareness and adoption of such products post the onset of the COVID-19 outbreak, this market is abuzz with activity to develop kits for detection, diagnosis and screening purposes
Roots Analysis has announced the addition of “At-home Self-testing Kits Market, 2022–2035” report to its list of offerings.
The report features an extensive study of the current market landscape and the likely future potential associated with the at-home self-testing kits market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:
A detailed overview of the current market landscape of companies engaged in the development of at-home self-testing kits, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters and others
A detailed analysis of academic grants that have been awarded to various research institutes for conducting research focused on at-home self-testing kits, during the period, pre-2019-2022, based on several parameters, such as year of grant award, amount awarded, support period, type of funding institute center, grant application, purpose of grant award, grant activity code, NIH spending category, study section involved, popular NIH departments, recipient organization, regional distribution of recipient organization.
A detailed competitiveness analysis of at-home self-testing kit manufacturers based on overall experience of the company (in terms of number of years since its establishment), product portfolio strength (in terms of number of at-home self-testing kits offered) and portfolio diversity (in terms of type of test format, type of biofluid analyzed, number of regulatory approvals, kit reusability, accessibility, and number of target analytes).
Elaborate profiles of prominent players engaged in offering at-home self-testing kits. Each profile includes a brief overview of the company, along with details related to its financial information (if available), information on product portfolio, recent developments, and an informed future outlook.
A Bowman's strategy clock framework to understand the pricing strategy of the at-home self-testing kits offered by a company, along with its competitive position in the market. In addition, it presents the equation devised to calculate the likely price of the at-home self-testing kits based upon its characteristics.
An estimate of company's intrinsic value by utilizing comparable company analysis of publicly listed companies based on their current share price, equity value, enterprise value, EBITDA, net income, and revenue.
An informed estimate of the annual demand (in terms of number of kits) for at-home self-testing kits, across various therapeutic areas, such as fertility and reproductive health, metabolic disorders, infectious diseases, and oncological disorders.
A detailed analysis based on a proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
An overview of at-home self-testing kits, highlighting the key steps involved while performing at-home self-tests, types of home-tests and types of assays used. The chapter also elaborates on the advantages offered by at-home self-testing kits along with the associated challenges. In addition, the chapter provides information on different regulatory authorities across key geographies which are involved in regulating the approval, safety, and sales of at-home self-testing kits
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Test Format
Strip Format
Stick Format
Cassette Format
Others
Type of Biofluid Analyzed
Blood
Urine
Stool
Target Therapeutic Area
Metabolic Disorders
Fertility and Reproductive Health
Infectious Diseases
Oncological Disorders
Key Geographical Regions
North America
Europe
Asia-Pacific
Africa
South America
Key companies covered in the report
ACON Laboratories
AdvaCare Pharma USA
Apex Biotechnology
i-SENS
Oak Tree Health
Tai Doc Technology
VivaChek Laboratories
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/self-testing-kits-market.html
You may also be interested in the following titles:
Non-Viral Transfection Reagents and Systems Market
Deep Learning in Drug Discovery Market and Deep Learning in Diagnostics Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
Bacteriophage Therapy is an attractive approach to tackle the escalating resistance against antibiotics; over the years, this upcoming class of target specific therapeutic agents has generated significant enthusiasm within the medical science community
Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings.
The report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the bacteriophage therapeutics market.
The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:
A summary of the key insights from the bacteriophage therapeutics market. It offers a high-level view on the current state of the market and its likely evolution in the mid to long term.
A general overview of the historical evolution of bacteriophages and their biology. It also includes a detailed discussion on applications of bacteriophage therapy. The chapter concludes with a discussion on the various advantages and limitations associated with the bacteriophage therapy.
A detailed overview of the overall market landscape of bacteriophage therapeutics, including information on their current status of development, key therapeutic areas, type of bacterial strain, target disease indication, type of therapy, route of administration, and information on bacteriophage related technologies.
An overview of the current status of the market with respect to the players engaged in the manufacturing of bacteriophage therapeutics, featuring information on the year of establishment, company size, location of headquarters, and leading developers.
Elaborate profiles of the prominent players engaged in the development of bacteriophage therapeutics.
An in-depth analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, trial phase, enrolled patient population, study design, type of sponsor / collaborator, most active players, registered trials, and geographical region.
An in-depth analysis of the various patents that have been filed / granted related to bacteriophage therapeutics. It includes information on key parameters. It also highlights the leading industry and non-industry players and individual assignees.
An in-depth analysis of various publications for bacteriophage therapeutics, based on several relevant parameters, such as year of publication, type of article, popular keywords, most popular publishers, key journals. It also highlights benchmarking of the publications to develop more insightful opinions on the recent trends related to research and development in this area.
A detailed study of the various grants that have been awarded to research institutes engaged in projects related to bacteriophage therapeutics, since 2017, highlighting various important parameters.
An in-depth analysis of the investments made, including grants, venture capital financing, initial public offering, secondary offering, private placement, equity and debt funding, at various stages of development, in companies that are focused on developing bacteriophage therapeutics.
A detailed study of the recent collaborations and partnership established in this domain since 2017, including the details of deals that were / are focused on the development of bacteriophage therapeutics.
An analysis of the various start-ups engaged in the development of bacteriophage therapeutics, based on relevant parameters, such as pipeline strength, pipeline maturity, indication diversity, number of patents, financial support and partnership activity
The financial opportunity within the bacteriophage therapeutics market has been analyzed across the following segments:
Type of Therapeutic Area
Gastrointestinal Infections
Bacterial Dysentery
Multiple Infections
Other Infections
Distribution by Route of Administration
Oral Route
Rectal Route
Intravesical Route
Topical Route
Key Geographical Regions
North America
Europe
Asia-Pacific
Latin America
Middle East and North Africa
Key Companies covered in the report
Adaptive Phage Therapeutics
ContaFect
Eliava BioPreparations
Micreos
NPO Microgen
Phagelux
Pherecydes Pharma
For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html
You may also be interested in the following titles:
Pharmaceutical Polymers / Medical Polymers Market
Gene Switch Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com